This provider's $20.0M in total Medicare payments ranks in the 95th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 2729% from 2014 to 2019.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 379% in 2018
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $26.44 | $15.59 | 1.70x | $10.85 | $351.7K | 31.2K | 23.3K |
| 2015 | $24.95 | $13.15 | 1.90x | $11.80 | $961.7K | 83.0K | 68.0K |
| 2016 | $71.69 | $17.74 | 4.04x | $53.95 | $1.4M | 110.1K | 74.2K |
| 2017 | $83.12 | $13.55 | 6.13x | $69.57 | $1.3M | 108.5K | 68.8K |
| 2018 | $171.00 | $59.10 | 2.89x | $111.90 | $6.1M | 111.3K | 84.5K |
| 2019 | $189.70 | $129.80 | 1.46x | $59.90 | $10.0M | 41.9K | 30.6K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 81408 | Molecular pathology procedure level 9 | 3.1K | $6.0M | $2.0K | 1.28x |
| 81407 | Molecular pathology procedure level 8 | 2.5K | $2.1M | $829.34 | 1.30x |
| 81317 | Gene analysis (postmeiotic segregation increased 2 [S cerevisiae]) full sequence analysis | 2.6K | $1.7M | $673.71 | 1.35x |
| 81201 | Gene analysis (adenomatous polyposis coli), full gene sequence | 2.1K | $1.6M | $764.40 | 1.34x |
| 81406 | Molecular pathology procedure level 7 | 3.0K | $835.0K | $276.95 | 1.32x |
| 84443 | Blood test, thyroid stimulating hormone (TSH) | 26.0K | $568.0K | $21.85 | 3.71x |
| 82306 | Vitamin D-3 level | 14.2K | $546.4K | $38.61 | 3.55x |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | 39.6K | $399.6K | $10.08 | 3.27x |
| 80053 | Blood test, comprehensive group of blood chemicals | 33.5K | $351.9K | $10.52 | 4.08x |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | 27.1K | $349.4K | $12.87 | 4.45x |
| 81435 | Test for detecting genes associated with colon cancer | 485 | $296.9K | $612.08 | 1.33x |
| G0483 | Drug test def 22+ classes | 897 | $212.2K | $236.60 | 10.88x |
| 81432 | Test for detecting genes associated with inherited breast cancer-related disorders | 286 | $207.1K | $723.98 | 1.43x |
| 83036 | Hemoglobin A1C level | 16.4K | $206.8K | $12.60 | 3.56x |
| 81162 | Gene analysis (breast cancer 1 and 2) of full sequence and analysis for duplication or deletion variants | 96 | $190.8K | $2.0K | 1.31x |
| 81401 | Molecular pathology procedure level 2 | 1.3K | $175.9K | $134.17 | 1.49x |
| 84480 | Thyroid hormone, T3 measurement | 9.0K | $166.4K | $18.41 | 2.67x |
| 81225 | Gene analysis (cytochrome P450, family 2, subfamily C, polypeptide 19) common variants | 574 | $163.9K | $285.53 | 1.04x |
| 81405 | Molecular pathology procedure level 6 | 538 | $158.9K | $295.32 | 1.26x |
| 82607 | Cyanocobalamin (vitamin B-12) level | 7.6K | $148.7K | $19.51 | 2.54x |
This provider submits charges 1.99 times higher than what Medicare actually pays.
A markup ratio of 1.99x means for every $100 Medicare pays, this provider initially charges $199. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in NJ for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Laboratory Corporation Of America Holdings | Raritan, NJ | $1.2B | ⚠️ Flagged |
| Quest Diagnostics Incorporated | Clifton, NJ | $927.2M | ⚠️ Flagged |
| Bioreference Health, Llc | Elmwood Park, NJ | $841.0M | ⚠️ Flagged |
| Accu Reference Medical Lab, Llc | Linden, NJ | $204.9M | ⚠️ Flagged |
| Aculabs Inc | East Brunswick, NJ | $91.5M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data